Oncology · Immune-mediated response
What is happening with ONX-7 right now?
Synthetic demo data
Active patients
500
Strong responders
193 / 39%
At-risk patients
39
Intervention opportunities
9
match trajectories that benefited from GI-04
Predicted discontinuations / 30 d
22
Emerging clusters
3
Predicted vs observed
Baseline model expectation against what the trajectories actually did.
| Metric | Predicted | Observed |
|---|---|---|
| Response | 58% | 69% |
| Severe GI toxicity | 6% | 3% |
| Discontinuation | 8% | 4% |
| Treatment persistence | 90% | 95% |
LIFE OS learned this week
All insightsA new treatment-response phenotype emerged
28 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 30; clinical recognition has typically come at day 77.
9 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 18% and 71% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 6.8× more likely to reach high discontinuation risk than the program average (57 patients).
Unexpected strong responders
42 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.